Korean J Clin Pharm.  2022 Sep;32(3):226-237. 10.24304/kjcp.2022.32.3.226.

Identifying the Patterns of Adverse Drug Responses of Cetuximab

• Park JH

• KMID: 2533902
• DOI: http://doi.org/10.24304/kjcp.2022.32.3.226

Abstract

Background
Monoclonal antibodies for the treatment of patients with different types of cancer, such as cetuximab, have been widely used for the past 10 years in oncology. Although drug information package insert contains some representative adverse events which were observed in the clinical trials for drug approval, the overall adverse event patterns on the real-world cetuximab use were less investigated. Also, there have been no published papers that deal with the full spectrums of adverse drug events of cetuximab using national-wide drug safety surveillance systems.
Methods
In this study, we detected new adverse event signals of cetuximab in the Korea Adverse Event Reporting System (KAERS) by utilizing proportional reporting ratios, reporting odds ratios, and information components indices.
Results
The KAERS database included 869,819 spontaneous adverse event reports, among which 2,116 reports contained cetuximab. We compared the labels of cetuximab among the United States, European Union, Australia, Japan, and Korea to compare the current labeling information and newly detected signals of our study. Some of the signals including hyperkeratosis, tenesmus, folliculitis, esophagitis, neuralgia, disseminated intravascular coagulopathy, and skin/throat tightness were not labeled in the five countries.
Conclusion
We identified new signals that were not known at the time of market approval.

Keyword

Cetuximab; adverse drug event; individual case safety report; pharmacovigilance; signal detection